Loading
The ordinary type of prostate cancer, more than 95 in every 100 cases. If a report says acinar adenocarcinoma it is saying the cancer is the usual kind, which is the kind every guideline, trial and survival figure for prostate cancer is about.
Acinar adenocarcinoma arises from the small glands, the acini, that make prostatic fluid, and accounts for more than 95 percent of prostatic carcinomas (RCPath G084). Everything written about prostate cancer without a qualifier is written about it: the Gleason grading system was built on it, the Cambridge Prognostic Groups and the NCCN bands stratify it, and the treatment trials from ProtecT to PSMAddition enrolled it. Because it is the default, the word appears on a report to distinguish it from the rare alternatives rather than to say anything about how the cancer will behave, which is decided by the grade group, the PSA and the stage.
The fifth edition of the WHO Classification of Tumours lists unusual morphologies of acinar adenocarcinoma as subtypes or as alternative histological patterns: PIN-like carcinoma, moved in this edition from being a pattern of ductal carcinoma to a subtype of acinar adenocarcinoma and graded Gleason 6 only; and atrophic, pseudohyperplastic, microcystic, foamy-gland, mucinous and signet-ring-like patterns, described so that pathologists recognise them rather than because they change management. None of these is a separate disease, and none has its own page here. The types that are separate in the fifth edition are ductal adenocarcinoma, treatment-related neuroendocrine prostatic carcinoma, adenoid cystic (basal cell) carcinoma, and squamous and adenosquamous carcinoma.
About three quarters of cancers arise in the peripheral zone at the back of the gland, the part a finger or a biopsy needle reaches; drainage is to the obturator and iliac nodes.
Same organ: Ductal adenocarcinoma of the prostate, Localised prostate cancer, very low and low risk, Localised prostate cancer, intermediate risk, Localised prostate cancer, high and very high risk, Biochemical recurrence of prostate cancer, Metastatic hormone-sensitive prostate cancer, Non-metastatic castration-resistant prostate cancer, Metastatic castration-resistant prostate cancer, Neuroendocrine and small-cell prostate cancer
Showing the organ this term concerns: Prostate cancer.
Shares Tumour differentiation (well / moderately / poorly differentiated), Intraductal carcinoma of the prostate (IDC-P), Ductal adenocarcinoma of the prostate, Gleason score / Grade Group.
Shares Neuroendocrine differentiation in prostate cancer, Neuroendocrine and small-cell prostate cancer, Prostate cancer.
Shares Tumour differentiation (well / moderately / poorly differentiated), Histology, Prostate cancer.
Shares Intraductal carcinoma of the prostate (IDC-P), Gleason score / Grade Group, Prostate cancer.
Shares Intraductal carcinoma of the prostate (IDC-P), Prostate cancer.
Shares Ductal adenocarcinoma of the prostate, Gleason score / Grade Group, Neuroendocrine and small-cell prostate cancer, Prostate cancer.
Shares Gleason score / Grade Group, Neuroendocrine and small-cell prostate cancer, Prostate cancer.
Shares Intraductal carcinoma of the prostate (IDC-P), Gleason score / Grade Group, Prostate cancer.